parainfluenza
viru
known
canin
parainfluenza
viru
veterinari
field
negativesens
nonseg
singlestrand
rna
viru
belong
paramyxovirida
famili
parainfluenza
viru
excel
viral
vector
use
live
vaccin
kennel
cough
mani
year
dog
without
safeti
concern
grow
high
titer
mani
cell
type
genom
stabl
even
presenc
foreign
gene
insert
far
use
develop
vaccin
influenza
viru
respiratori
syncyti
viru
rabi
viru
mycobacterium
tuberculosi
demonstr
abil
elicit
robust
protect
immun
respons
preclin
anim
model
parainfluenza
viru
vaccin
administ
intranas
intramuscularli
oral
interestingli
prior
exposur
prevent
vaccin
gener
robust
immun
indic
vector
use
encourag
result
review
togeth
along
discuss
desir
advantag
vaccin
vector
aid
futur
vaccin
design
acceler
progress
vaccin
clinic
trial
anim
infecti
diseas
human
infecti
diseas
parainfluenza
viru
vaccin
vector
infect
human
anim
includ
dog
pig
cat
hamster
guinea
pig
cattl
panda
parainfluenza
viru
first
isol
contamin
simian
cell
thu
name
simian
viru
howev
suffici
evid
subsequ
studi
indic
simian
viru
therefor
viru
subsequ
renam
intern
committe
taxonomi
virus
notabl
renam
mammalian
rubulaviru
name
use
review
parainfluenza
viru
associ
human
diseas
creutzfeldtjakob
diseas
multipl
sclerosi
common
cold
subsequ
studi
unabl
confirm
etiolog
agent
diseas
parainfluenza
viru
thought
contribut
upper
respiratori
infect
dog
common
compon
vaccin
design
prevent
canin
infecti
respiratori
diseas
also
known
kennel
cough
infect
dog
lead
respiratori
ill
indic
alon
pathogen
dog
veterinari
vaccin
contain
live
use
dog
least
year
without
safeti
concern
suggest
safe
first
rescu
rabi
viru
rabv
clone
cdna
mark
major
mileston
field
nonseg
negativestrand
rna
viru
nnsv
research
sinc
revers
genet
system
nnsv
develop
becom
power
tool
basic
viru
research
translat
research
includ
use
vaccin
vector
prevent
infecti
diseas
deliveri
vector
gene
therapi
past
decad
nnsv
member
includ
sendai
viru
vesicular
stomat
abbrevi
adenoviru
ctl
cytotox
lymphocyt
ge
gene
end
gfp
green
fluoresc
protein
gmcsf
granulocytemacrophag
colonystimul
factor
gs
gene
start
hpai
highli
pathogen
avian
influenza
im
intramuscular
intranas
ifn
interferon
na
neuraminidas
ndv
newcastl
diseas
viru
nnsv
nonseg
negativestrand
rna
viru
nt
nucleotid
pfu
plaqueform
unit
parainfluenza
viru
rabv
rabi
viru
rsv
respiratori
syncyti
viru
sc
subcutan
tb
tuberculosi
vv
vaccinia
viru
viru
ndv
rabv
extens
explor
applic
parainfluenza
viru
also
emerg
novel
attract
vector
vaccin
studi
parainfluenza
viru
nnsv
member
infect
host
respiratori
epithelium
make
attract
vector
develop
livevector
vaccin
induc
protect
mucos
immun
respons
far
number
vaccin
candid
success
protect
viral
bacteri
infect
multipl
anim
model
suggest
vector
highli
worthi
explor
field
vaccin
research
first
review
vaccin
human
anim
infecti
diseas
tabl
along
discuss
advantag
vaccin
vector
platform
aid
futur
vaccin
design
acceler
progress
vaccin
clinic
trial
parainfluenza
viru
nonseg
genom
consist
singl
strand
negativesens
rna
nucleotid
nt
length
total
length
viru
genom
multipl
encapsid
n
protein
provid
protect
nucleas
digest
genom
flank
sequenc
includ
nonoverlap
gene
order
encod
nucleocapsid
protein
np
v
protein
v
phosphoprotein
p
matrix
protein
fusion
protein
f
small
hydrophob
protein
sh
hemagglutininneuraminidas
hn
rna
polymeras
larg
protein
l
v
encod
singl
gene
vp
deriv
unedit
rna
p
gener
rna
edit
vp
gene
insert
two
nontempl
guanin
nucleotid
transcript
result
frame
shift
translat
rnadepend
rna
polymeras
consist
two
protein
p
l
l
protein
respons
major
enzymat
activ
involv
viral
rna
replic
transcript
well
addit
cap
structur
poli
sequenc
parainfluenza
viru
rna
genom
includ
negativesens
genom
positivesens
antigenom
encapsid
np
form
helic
ribonucleoprotein
essenti
viru
assembl
bud
genom
contain
noncod
region
gene
junction
gene
rang
size
approxim
nt
noncod
region
involv
gene
end
ge
transcript
signal
intergen
region
gene
start
gs
signal
ge
gs
signal
control
transcript
termin
reiniti
upstream
downstream
gene
polar
mechan
transcript
result
gradient
mrna
abund
highest
end
genom
decreas
toward
end
follow
order
np
vp
f
sh
hn
l
figur
construct
recombin
virus
express
foreign
gene
revers
genet
system
rescu
first
establish
viru
rescu
clone
cdna
contain
full
genom
sequenc
positivesens
orient
flank
promot
hepat
delta
viru
ribozym
rescu
cell
infect
recombin
vaccinia
viru
express
rna
polymeras
transfect
molecular
clone
along
helper
plasmid
encod
np
p
l
gene
viral
rna
synthes
rna
polymeras
encapsid
np
associ
polymeras
complex
compos
p
l
polymeras
complex
transcrib
replic
genom
progeni
use
place
cell
anoth
approach
prefer
use
laboratori
involv
construct
eukaryot
plasmid
rna
polymeras
cotransfect
infecti
clone
plasmid
np
p
lencod
plasmid
figur
method
ad
benefit
enabl
viru
rescu
neutral
antirabi
antibodi
attenu
rabv
vaccin
also
safeti
concern
inject
human
brain
respiratori
syncyti
viru
one
lead
caus
respiratori
ill
result
mortal
morbid
young
children
immunocompromis
individu
senior
citizen
thu
far
licens
rsv
vaccin
safe
efficaci
rsv
vaccin
remain
unmet
need
two
vaccin
express
rsv
glycoprotein
f
g
evalu
anim
model
immunogen
efficaci
protect
rsv
infect
first
examin
mice
proofofconcept
test
found
serum
neutral
antibodi
gener
mice
mice
despit
reduc
viral
burden
found
lung
mice
presum
rsv
gspecif
antibodi
protect
independ
convent
neutral
activ
vitro
work
demonstr
singledos
immun
elicit
protect
immun
rsv
challeng
mice
evalu
singledos
inocul
relev
preclin
anim
model
cotton
rat
elicit
rsvspecif
serum
antibodi
confer
complet
protect
lung
rsv
challeng
african
green
monkey
confer
greatest
reduct
postchalleng
rsv
titer
respiratori
tract
rel
less
efficaci
vaccin
also
abl
boost
rsv
neutral
antibodi
respons
african
green
monkey
prior
exposur
rsv
studi
demonstr
promis
vaccin
vector
rsvexpos
person
pediatr
elderli
rsv
infect
superior
rsv
vaccin
candid
recent
addit
work
publish
improv
vaccin
candid
contain
vector
rsvf
antigen
modif
effort
use
virus
deliveri
vector
vaccin
fraught
difficulti
field
human
veterinari
medicin
human
anim
preexist
immun
especi
neutral
antibodi
viral
vector
theoret
inhibit
viru
entri
host
cell
therebi
reduc
dose
antigen
vector
antigen
determin
presenc
preexist
immun
detriment
efficaci
vaccin
dog
prior
exposur
inocul
efficaci
ha
influenza
viru
subtyp
measur
dog
seroconvert
week
postinocul
hemaggluitin
inhibit
antibodi
titer
viru
greater
consid
protect
immunolog
standard
week
postinocul
result
indic
prior
exposur
prevent
vaccin
gener
protect
immun
result
consist
previou
find
antibodi
prevent
infect
mice
exposur
human
popul
also
investig
neutral
antibodi
detect
human
serum
sampl
titer
lower
dog
prior
exposur
result
suggest
vaccin
may
abl
overcom
preexist
immun
induc
immunogen
protect
immun
respons
pathogen
infect
human
safeti
alway
critic
concern
vaccin
research
develop
previous
mention
highli
stabl
genom
replic
cytoplasm
elimin
possibl
viral
genom
integr
dna
host
cell
parainfluenza
viru
consid
nonpathogen
low
virul
multipl
anim
speci
human
therefor
concern
virul
revers
residu
virul
use
vaccin
vector
unlik
liveattenu
pathogen
vector
concern
express
foreign
viral
envelop
protein
use
vaccin
vector
may
expand
tropism
pathogen
viral
vector
thu
far
evid
indic
occur
vaccin
research
exampl
vaccin
express
influenza
viru
ha
protein
test
nude
mice
address
issu
potenti
enhanc
pathogen
sign
ill
weight
loss
observ
immunedefici
mice
infect
consist
find
recombin
ferret
mice
display
clinic
sign
diseas
discern
patholog
ideal
virusvector
vaccin
elicit
robust
b
cellmedi
protect
humor
immun
respons
also
gener
antigenspecif
cell
cell
previous
discuss
vector
abl
induc
strong
humor
immun
protect
varieti
vaccin
target
induct
cellular
immun
also
critic
protect
pathogen
induct
cellular
immun
investig
depth
abil
induc
cellular
immun
respons
test
use
express
model
antigen
chicken
ovalbumin
experi
mice
inocul
intranas
tcell
respons
assess
vaccin
elicit
strong
longlast
cytotox
lymphocyt
ctl
respons
high
avid
ovalbumin
result
suggest
good
vaccin
vector
viral
antigen
sinc
high
avid
ctl
respons
optim
viru
clearanc
sinc
replic
primarili
occur
respiratori
tract
qualiti
make
attract
vaccin
vector
gener
high
avid
ctl
respons
respiratori
mucos
pathogen
infect
tremend
advanc
viral
vaccin
vector
develop
made
past
decad
advanc
reli
improv
understand
viral
biolog
updat
insight
reciproc
interact
virus
host
immun
system
current
viral
vector
vaccin
remain
one
best
strategi
induct
robust
humor
cellular
immun
human
anim
infecti
diseas
parainfluenza
viru
becom
attract
vector
field
vaccin
research
particularli
develop
vaccin
requir
induct
protect
mucos
immun
respons
use
vector
appear
pose
major
risk
anim
human
health
concern
virul
revers
residu
virul
viru
recombin
futur
design
immun
strategi
vector
optim
induc
potent
complet
protect
immun
anim
human
reduc
diseas
defend
infecti
pathogen
